Secoisolariciresinol Diglucoside (SDG) from Flaxseed in the Prevention and Treatment of Diabetes Mellitus
Management of diabetes with SDG
Abstract
This review focuses on the role of reactive oxygen species (ROS) on the development of type 1 and type 2 diabetes and its treatment with secoisolariciresinol diglucoside (SDG) isolated from flaxseed which is an antioxidant and suppresses phosphoenolpyruvate carboxykinase (PEPCK) gene expression, a rate- limiting enzyme in the gluconeogenesis in the liver. Role of ROS in the development of type 1 diabetes [diabetic prone Bio Breeding (BBdp) rats and streptozotocin-induced diabetic (STZ) rats and type 2 diabetes (Zucker diabetic fatty female rats, ZDF rats)] has been discussed. Oxidative stress has been assessed by measuring serum and pancreatic malondialdehyde (MDA), pancreatic chemiluminescence (pancreatic-CL) and oxygen radical producing activity of white blood cells (WBC-CL). Diagnosis of diabetes was made by hyperglycaemia and glucosuria. Incidence of diabetes was 100 % in SDZ rats, 72 % in BBdp rats and 100 % in ZDF rats by the age of 72 days. Development of diabetes was associated with increases in the serum and pancreatic MDA, WBC-CL and pancreatic-CL and glycated haemoglobin (HbA1c). SDG prevented the development of diabetes by 75 % in STZ rats, by 71 % in BBdp rats and by 20 % at 72 days of age in ZDF rats. However, 80 % of the rats which did not develop diabetes by 72 days of age, developed diabetes later on, suggesting that SDG treatment delays the development of diabetes in ZDF rats. Treatment with SDG decreased the levels of serum and pancreatic MDA, WBC-CL and pancreatic-CL. In conclusion, development of type 1 and type 2 diabetes is mediated through oxidative stress and the prevention or delay in the development of diabetes with SDG could be due to its antioxidant activity and its suppressant effect on PEPCK enzyme. Lignan complex which contains 34 % to 38 % of SDG is effective in lowering serum glucose and HbA1c in type 2 diabetes in humans.
References
1. Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Hosseini Fard H, Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot Perspect 2020;10:98-115.
2. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health 2020 Mar;10(1):107-11.
3. Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS. Epidemiology, public health burden and treatment of diabetic peripheral neuropathic pain: a review. Pain Med 2007 Sep;8 Suppl 2:S50-62.
4. Dugani SB, Mielke MM, Vella A. Burden and management of type 2 diabetes in rural United States. Diabetes Metab Res Rev 2021;37:e3410. doi: 10.1002/dmrr.3410.
5. Oomah B D, Mazza G. Flaxseed proteins: a review. Food Chem1993;48:109-14.
6. Hettiarachchy NS, Hareland GA, Ostenson A, Bladner-Shank G. Chemical composition of flaxseed varieties grown in North Dakota. Proc Flax Institute 1990;53:36-50.
7. Prasad K, Mantha SV, Muir AD, Westcott ND. Reduction of hypercholesterolemic atherosclerosis by CDC-flaxseed with very low alpha-linolenic acid. Atherosclerosis 1998;136:367-75.
8. Hano C, Martin I, Fliniaux O. Pinoresinol-lariciresinolreductase gene expression and secoisolariciresinoldiglucoside accumulation in developing flax (Linum usitatissimum) seeds. Planta 2006;224:1291-301.
9. Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation 1999;99:1355-62.
10. Bakke JE, Klosterman JHJ.A new diglucoside from flaxseed. Proc North Dakota Acad Sci1956;10:18-22.
11. Westcott ND, Paton D. Complex containing lignan, phenolic and aliphatic substances from flax and process for preparing. US Patent 6, 334, 557. December 28, 2000.
12. Bernacchia R, Preti R, Vinci G. Chemical composition and health benefits of flaxseed. Austin J Nutri Food Sci 2014;2:1045:1-9.
13. Robbins MJ, Sharp RA, Slonim AE, Burr IM. Protection against streptozotocin-induced diabetes by superoxide dismutase. Diabetologia 1980;18:55-8.
14. Wilson GL, Patton NJ, McCord JM, Mullins DW, Mossman BT. Mechanism of streptozotocin- and alloxan-induceddamage in rat β-cells. Diabetologia 1984;27:587-91.
15. Jennings PE, Jones AF, Florkowski CM, Lunec J, Barnett AH. Increased Diene conjugates in diabetic subjects with microangiography. Diabet Med 1987;4:452-6.
16. Paolisso G, Giugliano D. Oxidative stress and insulin action: Is there a relationship? Diabetologia 1996;39:357-63.
17. Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, Betteridge DJ, Wolff SP. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 1995;44:1054-8.
18. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004 May;24(5):816-23.
19. Prasad K. Hydroxyl radical-scavenging property of secoisolariciresinol diglucoside (SDG) isolated from flax-seed. Mol Cell Biochem 1997;168:1217-23.
20. Prasad K. Antioxidant activity of secoisolariciresinol diglucoside-derived metabolites, secoisolariciresinol, enterodiol and enterolactone. Int J Angiol 2000 Oct;9(4):220-5.
21. Babior BM. The respiratory burst of phagocytes. J Clin Invest 1984;73:599-601.
22. Prasad K, Kalra J, Chaudhary AK, Debnath D. Effect of polymorphonuclear leukocyte-derived oxygen free radicals and hypochlorous acid on cardiac function and some biochemical parameters. Am Heart J 1990;119:538-50.
23. Consoli A, Nurjhan N, Capani F, Gerich J. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 1989;38:550-7.
24. Hatting M, Tavares CDJ, Sharabi K, Rines AK, Puigserver P. Insulin regulation of gluconeogenesis. Ann NY Acad Sc 2018;1411:21-35.
25. Rognstad R. Rate-limiting steps in metabolic pathways. J Biol Chem 1979;254:1875-8.
26. Nandan SD, Beale EG Regulation of phosphoenolpyruvate carboxykinase mRNA in mouse liver, kidney and fat tissues by fasting, diabetes and insulin. Lab Anim Sci 1992;42:473-7.
27. Veneziale CM, Donofrio JC, Nishimura H. The concentration of P-enolpyruvate carboxykinase protein in murine tissues in diabetes of chemical and genetic origin. J Biol Chem 1983;258:14257-62.
28. Chang AY, Schneider D. Abnormalities in hepatic enzyme activities during development of diabetes in db mice. Diabetologia 1970;6:274-8.
29. Shargo E, Lardy HA, Nordlie RC, Fraser DO. Metabolic and hormonal control of phosphoenolpyruvate carboxykinase and malic enzyme in rat liver. J Biol Chem 1963;238:3188-92.
30. Loose DS, Wynshaw-Boris A, Meisner HM, Dod Y, Hanson RW. Hormonal regulation of phosphoenolpyruvate carboxykinase gene expression. In: Molecular basis of insulin action. Czech MP (ed.) Plenum:New York, 1985; pp. 347-368.
31. Prasad K. Suppression of phosphoenolpyruvate carboxykinase gene expression by secoisolariciresinol diglucoside (SDG), a new antidiabetic agent. Int J Angiol 2002;1:107-9.
32. Davies GF, Khandelwal RL, Wu L, Juurlink BHJ, Roesler WJ. Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-γ (PPAR γ)-independent, antioxidant-related mechanism. Biochem Pharmacol 2001;62:1071-9.
33. Inoue I, Katayama S, Takahashi K, Negishi K, Miyazaki T, Sonoda M, et al. Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun 1997 Jun 9;235(1):113-6.
34. Nathan CF, Tsunawaki S. Secretion of toxic oxygen products by macrophages: Regulatory cytokines and their effect on the oxidase. Ciba Foundation Symposium 1986;118:211-30.
35. Braquet P, Hosfard D, Braquet M, Bourgain R, Bussolino F. Role of cytokines and platelet activating factor in microvascular injury. Int Arch Allerg Appl Immunol 1989;88:88-100.
36. Paubert-Braquet M, Longchamps MA, Kolz P. Tumor necrosis factor (TNF) primes human neutrophil (PMN) platelet-activating factor (PAF)-induced superoxide generation. Consequences in promoting PMN-mediated endothelial cell (EC) damages. Prostaglandins 1988;35:(abstr)803.
37. Meerson FZ, Kagan VE, Kozlov YP, Belkina LM, Arkhipenko YV. The role of lipid peroxidation in pathogenesis of ischemic damage and antioxidant protection of the heart. Basic Res Cardiol 1982;77:465-8.
38. Sumoski W, Baquerizo H, Rabinovitch A. Oxygen radical scavengers protect rat islet cells from damage by cytokines. Diabetologia 1989;32:792-6.
39. Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne) 2013 Mar 27;4:37. doi: 10.3389/fendo.2013.00037.
40. Rabinovitch A, Suarez WL, Thomas PD, Strynadka K, Simpson I. Cytotoxic effects of cytokines on rat islets: Evidence for involvement of free radicals and lipid peroxidation. Diabetologia 1992;35:409-13.
41. Prasad K, Mantha SV, Muir AD, Westcott ND. Protective effect of secoisolariciresinol diglucoside against streptozotocin-induced diabetes and its mechanism. Mol Cell Biochem 2000;206:141-9.
42. Prasad K. Oxidative stress as a mechanism of diabetes in diabetic BB prone rats: effect of secoisolariciresinol diglucoside (SDG). Mol Cell Biochem 2000;209:89-96.
43. Prasad K. Secoisolariciresinol diglucoside from flaxseed delays the development of type 2 diabetes in Zucker rat. J Lab Clin Med 2001;138:32-9.
44. Mordes JP, Desemone J, Rossini AA. The BB rat. Diabetes Metab Rev 1987;3:725-50.
45. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997; 82:291-5.
46. Pan A, Sun J, Chen Y, Ye X, Li H, Yu Z, et al. Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: a randomized, double-blind, cross-over trial. PLoS One 2007 Nov 7;2(11):e1148. doi: 10.1371/journal.pone.0001148.
47. Barre DE, Mizier-Barre KA, Stelmach E, Hobson J, Griscti O, Rudiuk A, et al. Flaxseed lignan complex administration in older human type 2 diabetics manages central obesity and prothrombosis-an invitation to further investigation into polypharmacy reduction. J Nutr Metab 2012;2012:585170. doi: 10.1155/2012/585170.
48. Hall RK, Wang XL, George L, Koch SR, Granner DK. Insulin represses phosphoenolpyruvate carboxykinase gene transcription by causing the rapid disruption of an active transcription complex: a potential epigenetic effect. Mol Endocrinol 2007 Feb;21(2):550-63.
49. Newsholme P, Keane KN, Carlessi R, Cruzat V. Oxidative stress pathways in pancreatic β-cells and insulin-sensitive cells and tissues: importance to cell metabolism, function and dysfunction. Am J Physiol-Cell Physiol 2019;317:C420-C433.
50. Kaneto H, Xu G, Fujii N, Kim S, Bonner-Weir S, Weir GC. Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. J Biol Chem 2002 Aug 16;277(33):30010-8.
51. She P, Shiota M, Shelton KD, Chalkley R, Postic C, Magnuson MA. Phosphoenolpyruvate carboxykinase is necessary for the integration of hepatic energy metabolism. Mol Cell Biol 2000 Sep;20(17):6508-17.
52. Shao J, Qiao L, Janssen RC, Pagliassotti M, Friedman JE. Chronic hyperglycemia enhances PEPCK gene expression and hepatocellular glucose production via elevated liver activating protein/liver inhibitory protein ratio. Diabetes 2005 Apr;54(4):976-84.
53. Wolff SP, Dean RT. Glucose autoxidation and protein modification: the potential role of autoxidative glycosylation in diabetes. J Biochem 1987;245:243-50.
54. Prasad K, Gupta JB, Kalra J, Lee P, Mantha SV, Bharadwaj B. Oxidative stress as a mechanism of cardiac failure in chronic volume overload in canine model. J Mol Cell Cardiol 1996 Feb;28(2):375-85.
55. Setchell KD, Brown NM, Zimmer-Nechemias L, Wolfe B, Jha P, Heubi JE. Metabolism of secoisolariciresinol-diglycoside the dietary precursor to the intestinally derived lignan enterolactone in humans. Food Funct 2014;5:491-501.
56. Carraro JCC, de Souza Dantas MI, Espeschit ACR, Martino HSD, Ribeiro SMR. Flaxseed and human health: reviewing benefits and adverse effects. Food Rev Int 2012;28:203–30.
57. Davies GF, Khandelwal RL, Roesler WJ. Troglitazone inhibits expression of phosphoenolpyruvate carboxykinase gene by an insulin-independent mechanism. Biochem Biophys Acta 1999;1451:122–31.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).